Signaturefd LLC Sells 2,540 Shares of Novo Nordisk A/S (NYSE:NVO)

Signaturefd LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,107 shares of the company’s stock after selling 2,540 shares during the quarter. Signaturefd LLC’s holdings in Novo Nordisk A/S were worth $6,547,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of NVO. Raymond James Financial Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $404,910,000. Sustainable Growth Advisers LP lifted its stake in shares of Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares during the period. Amundi increased its stake in shares of Novo Nordisk A/S by 26.4% in the 4th quarter. Amundi now owns 3,311,456 shares of the company’s stock valued at $283,615,000 after purchasing an additional 692,567 shares in the last quarter. Parnassus Investments LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $51,072,000. Finally, DAVENPORT & Co LLC raised its position in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after acquiring an additional 451,641 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $77.22 on Monday. The firm has a market cap of $346.54 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The firm’s fifty day moving average price is $83.95 and its 200 day moving average price is $102.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1-year low of $73.80 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.